Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The discovery that aberrant Hedgehog signalling can lead to the development of basal cell carcinoma (BCC) has facilitated a remarkable increase in our understanding of BCC. How is this information being used to refine the treatment of this disease?
This Review assesses emerging data that indicate a specific role for the RB tumour suppressor pathway in the response of the haematopoietic system to oxidative stress, and discusses the relevance of these findings to future cancer therapies.
Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets for cancer therapy: both recombinant TRAIL and monoclonal antibodies that target these receptors have entered clinical trials. How are these agents faring? What are the current stumbling blocks?
Replication licensing proteins are inappropriately expressed and misregulated in a wide variety of cancers. What are the consequences for DNA replication and genomic stability?
Mutations in the bone morphogenetic protein pathway have been found in juvenile polyposis, an inherited polyposis syndrome that predisposes to colorectal cancer. What relevance do these findings have to sporadic cases of colorectal cancer?
High mammographic density (MD) is an established risk factor for breast cancer. In theory, the number of genes that regulate MD should be smaller than that influencing breast cancer risk. How informative have the initial studies of the genetics of MD proved to be?
